C
Christine L. Talarico
Researcher at Research Triangle Park
Publications - 24
Citations - 2000
Christine L. Talarico is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Human cytomegalovirus & Cabotegravir. The author has an hindex of 17, co-authored 23 publications receiving 1611 citations.
Papers
More filters
Journal ArticleDOI
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
V. Sullivan,Christine L. Talarico,Sylvia C. Stanat,Michele Davis,Donald M. Coen,Karen K. Biron +5 more
TL;DR: It is reported that the HCMV gene UL97, whose predicted product shares regions of homology with protein kinases, guanylyl cyclase and bacterial phosphotransferases, controls phosphorylation of ganciclovir in H CMV-infected cells.
Journal ArticleDOI
Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action
Karen K. Biron,Robert J. Harvey,Stanley C. Chamberlain,Steven S. Good,Albert A. Smith,Michelle G. Davis,Christine L. Talarico,Wayne H. Miller,Robert G. Ferris,R E Dornsife,Sylvia C. Stanat,John C. Drach,Leroy B. Townsend,George W. Koszalka +13 more
TL;DR: The mechanism of the antiviral effect of l-riboside 1263W94 is thus distinct from those of GCV and of BDCRB, including those resistant to ganciclovir, foscarnet, andBDCRB.
Journal ArticleDOI
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells,Jaime-Federico Andrade-Villanueva,Gary Richmond,Giuliano Rizzardini,Axel Baumgarten,Mar Masiá,Gulam H Latiff,Vadim Pokrovsky,Fritz Bredeek,Graham H R Smith,Pedro Cahn,Yeon Sook Kim,Susan L. Ford,Christine L. Talarico,Parul Patel,Vasiliki Chounta,Herta Crauwels,Wim Louis Julien Parys,Simon Vanveggel,Joseph M. Mrus,Jenny Huang,Conn M. Harrington,Krischan J Hudson,David A. Margolis,Kimberly Y. Smith,Peter Williams,William Spreen +26 more
TL;DR: In this paper, simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence, which may improve adherence.
Journal ArticleDOI
Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding
Jacob Lalezari,Judith A. Aberg,Laurene H. Wang,Mary Beth Wire,R C Miner,Wendy Snowden,Christine L. Talarico,Shuching Shaw,Mark A. Jacobson,W. Lawrence Drew +9 more
TL;DR: 1263W 94 demonstrated linear PK, with steady-state plasma 1263W94 profiles predictable based on single-dose data, and was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period.
Journal ArticleDOI
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T. Overton,Gary Richmond,Giuliano Rizzardini,Hans Jaeger,Catherine Orrell,Firaya Nagimova,Fritz Bredeek,Miguel García Deltoro,Susan Swindells,Jaime Andrade-Villanueva,Alexander Wong,Marie-Aude Khuong-Josses,Rodica Van Solingen-Ristea,Veerle Van Eygen,Herta Crauwels,Susan L. Ford,Christine L. Talarico,Paul D Benn,Yuanyuan Wang,Krischan J Hudson,Vasiliki Chounta,Amy Cutrell,Parul Patel,Mark S. Shaefer,David A. Margolis,Kimberly Y. Smith,Simon Vanveggel,William Spreen +27 more
TL;DR: The efficacy and safety profiles of dosingevery 8 weeks and dosing every 4 weeks were similar and support the use of cabotegravir plus rilpivirine long-acting in ATLAS, an open-label, phase 3b, non-inferiority study.